Story perspectives
New Drug Aficamten Boosts Exercise in HCM Patients
8/30/2025
49 12
1 of 1
Story summary
- A study on August 30, 2025, found that Cytokinetics' drug aficamten enhanced exercise capacity in obstructive hypertrophic cardiomyopathy (HCM) patients.
- Aficamten demonstrated a 1.1-point improvement in peak oxygen uptake compared to the beta blocker metoprolol.
- The FDA is currently reviewing aficamten for potential approval, which may broaden its application for HCM patients.
